Evogene (EVGN) Q4 2025 earnings summary

Executive summary

• Strategic transformation in 2025 focused on ChemPass AI for small molecule drugs and agriculture, discontinuing non-core activities and divesting misaligned assets.

• Streamlined operations, resized organization, and aligned business development to support the new focus.

• Advanced ChemPass AI through collaborations with Google Cloud, Bayer, and Corteva, achieving improvements in design precision.

• Divestiture of Lavie Bio to ICL and licensing of Biomica's lead candidate to Lishan Pharmaceuticals; both subsidiaries to distribute most remaining cash to shareholders.

• Business model centers on partnership-driven workflow and proprietary product pipeline development.

Financial highlights

• Operating expenses for 2025 decreased to $13.8M from $22M in 2024; Q4 operating expenses were $3.2M vs. $4.3M last year.

• Revenues for 2025 were $3.9M, down from $5.6M in 2024, mainly due to lower AgPlenus, Casterra, and Corteva contributions.

• Net loss for 2025 was $7.8M, a significant improvement from $18.1M in 2024, aided by lower expenses and income from discontinued operations.

• Cash and equivalents at year-end 2025 were $13M; Q4 cash usage was $3M.

• Operating loss for 2025 was $14M, down from $18.8M in 2024, driven by reduced operating expenses.

Outlook and guidance

• Reduced expense levels expected to be sustained in future periods following organizational realignment.

• Cash position expected to cover operational needs for at least 18 months post-dividend distributions from Lavie Bio and Biomica.

• Continued focus on advancing proprietary small-molecule candidates in pharma and agriculture, leveraging ChemPass AI and strategic partnerships.

• Anticipates further technology collaborations, pharma/biotech partnerships, and ag chemical agreements as key catalysts.